Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 92

1.

Advances in therapeutic targeting of the DNA damage response in cancer.

Desai A, Yan Y, Gerson SL.

DNA Repair (Amst). 2018 Jun - Jul;66-67:24-29. doi: 10.1016/j.dnarep.2018.04.004. Epub 2018 Apr 23. Review.

2.

Distinct roles of resident and nonresident macrophages in nonischemic cardiomyopathy.

Liao X, Shen Y, Zhang R, Sugi K, Vasudevan NT, Alaiti MA, Sweet DR, Zhou L, Qing Y, Gerson SL, Fu C, Wynshaw-Boris A, Hu R, Schwartz MA, Fujioka H, Richardson B, Cameron MJ, Hayashi H, Stamler JS, Jain MK.

Proc Natl Acad Sci U S A. 2018 May 15;115(20):E4661-E4669. doi: 10.1073/pnas.1720065115. Epub 2018 Apr 30.

PMID:
29712858
3.

MMR Deficiency Does Not Sensitize or Compromise the Function of Hematopoietic Stem Cells to Low and High LET Radiation.

Patel R, Qing Y, Kennedy L, Yan Y, Pink J, Aguila B, Desai A, Gerson SL, Welford SM.

Stem Cells Transl Med. 2018 Apr 14. doi: 10.1002/sctm.17-0295. [Epub ahead of print]

4.

A second-generation 15-PGDH inhibitor promotes bone marrow transplant recovery independently of age, transplant dose and granulocyte colony-stimulating factor support.

Desai A, Zhang Y, Park Y, Dawson DM, Larusch GA, Kasturi L, Wald D, Ready JM, Gerson SL, Markowitz SD.

Haematologica. 2018 Jun;103(6):1054-1064. doi: 10.3324/haematol.2017.178376. Epub 2018 Feb 22.

5.

Future cancer research priorities in the USA: a Lancet Oncology Commission.

Jaffee EM, Dang CV, Agus DB, Alexander BM, Anderson KC, Ashworth A, Barker AD, Bastani R, Bhatia S, Bluestone JA, Brawley O, Butte AJ, Coit DG, Davidson NE, Davis M, DePinho RA, Diasio RB, Draetta G, Frazier AL, Futreal A, Gambhir SS, Ganz PA, Garraway L, Gerson S, Gupta S, Heath J, Hoffman RI, Hudis C, Hughes-Halbert C, Ibrahim R, Jadvar H, Kavanagh B, Kittles R, Le QT, Lippman SM, Mankoff D, Mardis ER, Mayer DK, McMasters K, Meropol NJ, Mitchell B, Naredi P, Ornish D, Pawlik TM, Peppercorn J, Pomper MG, Raghavan D, Ritchie C, Schwarz SW, Sullivan R, Wahl R, Wolchok JD, Wong SL, Yung A.

Lancet Oncol. 2017 Nov;18(11):e653-e706. doi: 10.1016/S1470-2045(17)30698-8. Epub 2017 Oct 31. Review.

PMID:
29208398
6.

New Opportunities and Challenges to Defeat Cancer Stem Cells.

Ramos EK, Hoffmann AD, Gerson SL, Liu H.

Trends Cancer. 2017 Nov;3(11):780-796. doi: 10.1016/j.trecan.2017.08.007. Epub 2017 Sep 21. Review.

PMID:
29120754
7.

Loss of Uracil DNA Glycosylase Selectively Resensitizes p53-Mutant and -Deficient Cells to 5-FdU.

Yan Y, Qing Y, Pink JJ, Gerson SL.

Mol Cancer Res. 2018 Feb;16(2):212-221. doi: 10.1158/1541-7786.MCR-17-0215. Epub 2017 Nov 8.

PMID:
29117941
8.

Phase I clinical trial of the base excision repair inhibitor methoxyamine in combination with fludarabine for patients with advanced hematologic malignancies.

Caimi PF, Cooper BW, William BM, Dowlati A, Barr PM, Fu P, Pink J, Xu Y, Lazarus HM, de Lima M, Gerson SL.

Oncotarget. 2017 Aug 9;8(45):79864-79875. doi: 10.18632/oncotarget.20094. eCollection 2017 Oct 3.

9.

Long-Term Deficits in Behavior Performances Caused by Low- and High-Linear Energy Transfer Radiation.

Patel R, Arakawa H, Radivoyevitch T, Gerson SL, Welford SM.

Radiat Res. 2017 Dec;188(6):672-680. doi: 10.1667/RR14795.1. Epub 2017 Sep 29.

PMID:
28961076
10.

New Advances and Challenges of Targeting Cancer Stem Cells.

Dashzeveg NK, Taftaf R, Ramos EK, Torre-Healy L, Chumakova A, Silver DJ, Alban TJ, Sinyuk M, Thiagarajan PS, Jarrar AM, Turaga SM, Saygin C, Mulkearns-Hubert E, Hitomi M, Rich JN, Gerson SL, Lathia JD, Liu H.

Cancer Res. 2017 Oct 1;77(19):5222-5227. doi: 10.1158/0008-5472.CAN-17-0054. Epub 2017 Sep 19.

PMID:
28928129
11.

Mismatch repair deficient hematopoietic stem cells are preleukemic stem cells.

Qing Y, Gerson SL.

PLoS One. 2017 Aug 2;12(8):e0182175. doi: 10.1371/journal.pone.0182175. eCollection 2017.

12.

CCN3 Regulates Macrophage Foam Cell Formation and Atherosclerosis.

Shi H, Zhang C, Pasupuleti V, Hu X, Prosdocimo DA, Wu W, Qing Y, Wu S, Mohammad H, Gerson SL, Perbal B, Klenotic PA, Dong N, Lin Z.

Am J Pathol. 2017 Jun;187(6):1230-1237. doi: 10.1016/j.ajpath.2017.01.020.

13.

Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis.

Cohen JA, Imrey PB, Planchon SM, Bermel RA, Fisher E, Fox RJ, Bar-Or A, Sharp SL, Skaramagas TT, Jagodnik P, Karafa M, Morrison S, Reese Koc J, Gerson SL, Lazarus HM.

Mult Scler. 2018 Apr;24(4):501-511. doi: 10.1177/1352458517703802. Epub 2017 Apr 6.

PMID:
28381130
14.

Evaluation of O6-Benzylguanine-Potentiated Topical Carmustine for Mycosis Fungoides: A Phase 1-2 Clinical Trial.

Tacastacas JD, Chan DV, Carlson S, Gerson SL, Dowlati A, Fu P, Lu K, Groft S, Rosenjack J, Honda K, McCormick TS, Cooper KD.

JAMA Dermatol. 2017 May 1;153(5):413-420. doi: 10.1001/jamadermatol.2016.5793.

15.

Splenic marginal zone lymphoma: excellent outcomes in 64 patients treated in the rituximab era.

Starr AG, Caimi PF, Fu P, Massoud MR, Meyerson H, Hsi ED, Mansur DB, Cherian S, Cooper BW, De Lima MJG, Lazarus HM, Gerson SL, Jagadeesh D, Smith MR, Dean RM, Pohlman BL, Hill BT, William BM.

Hematology. 2017 Aug;22(7):405-411. doi: 10.1080/10245332.2017.1279842. Epub 2017 Jan 20.

PMID:
28105889
16.

Outcomes of allogeneic hematopoietic stem cell transplantation for lymphomas: a single-institution experience.

Massoud MR, Caimi PF, Ferrari N, Fu P, Creger R, Fox R, Carlson-Barko J, Kolk M, Brister L, Cooper BW, Gerson S, Lazarus HM, de Lima M, William BM.

Rev Bras Hematol Hemoter. 2016 Oct - Dec;38(4):314-319. doi: 10.1016/j.bjhh.2016.07.003. Epub 2016 Aug 18.

17.

Radiosensitization of non-small-cell lung cancer cells and xenografts by the interactive effects of pemetrexed and methoxyamine.

Oleinick NL, Biswas T, Patel R, Tao M, Patel R, Weeks L, Sharma N, Dowlati A, Gerson SL, Fu P, Zhang J, Machtay M.

Radiother Oncol. 2016 Nov;121(2):335-341. doi: 10.1016/j.radonc.2016.10.007. Epub 2016 Nov 9.

PMID:
27838149
18.

Epigenetic Loss of MLH1 Expression in Normal Human Hematopoietic Stem Cell Clones is Defined by the Promoter CpG Methylation Pattern Observed by High-Throughput Methylation Specific Sequencing.

Kenyon J, Nickel-Meester G, Qing Y, Santos-Guasch G, Drake E, PingfuFu, Sun S, Bai X, Wald D, Arts E, Gerson SL.

Int J Stem Cell Res Ther. 2016;3(2). pii: 031. Epub 2016 May 24.

19.

Inhibition of uracil DNA glycosylase sensitizes cancer cells to 5-fluorodeoxyuridine through replication fork collapse-induced DNA damage.

Yan Y, Han X, Qing Y, Condie AG, Gorityala S, Yang S, Xu Y, Zhang Y, Gerson SL.

Oncotarget. 2016 Sep 13;7(37):59299-59313. doi: 10.18632/oncotarget.11151.

20.

Dual institution experience of nodal marginal zone lymphoma reveals excellent long-term outcomes in the rituximab era.

Starr AG, Caimi PF, Fu P, Massoud MR, Meyerson H, Hsi ED, Mansur DB, Cherian S, Cooper BW, De Lima MJ, Lazarus HM, Gerson SL, Jagadeesh D, Smith MR, Dean RM, Pohlman BL, Hill BT, William BM.

Br J Haematol. 2016 Oct;175(2):275-280. doi: 10.1111/bjh.14228. Epub 2016 Jul 22.

PMID:
27443247

Supplemental Content

Loading ...
Support Center